Stock HAEK HAEMATO AG
Add to a list
To use this feature you must be a member
Log inSign up

Financials HAEMATO AG Deutsche Boerse AG

Equities

HAEK

DE000A289VV1

Pharmaceuticals

Market Closed - Deutsche Boerse AG
Other stock markets
 07:17:18 17/04/2024 pm IST 		5-day change 1st Jan Change
15.05 EUR +0.33% Intraday chart for HAEMATO AG +0.33% -44.26%

Valuation

Fiscal Period: December 2023 2024 2025
Capitalization 1 87.82 87.82 -
Enterprise Value (EV) 1 66.62 63.62 87.82
P/E ratio - - -
Yield - - -
Capitalization / Revenue 0.33 x 0.31 x 0.29 x
EV / Revenue 0.25 x 0.23 x 0.29 x
EV / EBITDA 5.14 x 4.39 x 5.38 x
EV / FCF 22.5 x 6.92 x -
FCF Yield 4.45% 14.5% -
Price to Book - - -
Nbr of stocks (in thousands) 5,228 5,228 -
Reference price 2 16.80 16.80 16.80
Announcement Date - - -
1EUR in Million2
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023 2024 2025
Net sales 1 274.1 197.8 238.3 285 248.1 268.1 281.1 302.6
EBITDA 1 9.959 - 3.315 12.64 9.661 12.95 14.51 16.31
EBIT 1 - - 1.627 11.16 8.295 11.62 13.24 14.99
Operating Margin - - 0.68% 3.92% 3.34% 4.33% 4.71% 4.95%
Earnings before Tax (EBT) 1 - - - 9.357 10.48 9.352 12.9 -
Net income 1 - - -4.831 6.862 8.193 7.863 10 11.02
Net margin - - -2.03% 2.41% 3.3% 2.93% 3.56% 3.64%
EPS - - - - - - - -
Free Cash Flow 1 - - 13.83 13.88 17.12 2.962 9.199 -
FCF margin - - 5.8% 4.87% 6.9% 1.1% 3.27% -
FCF Conversion (EBITDA) - - 417.11% 109.86% 177.22% 22.87% 63.42% -
FCF Conversion (Net income) - - - 202.3% 208.98% 37.67% 91.99% -
Dividend per Share - - - - - - - -
Announcement Date 08/05/19 30/04/20 26/05/21 17/05/22 08/05/23 - - -
1EUR in Million
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2022 Q1 2022 Q2 2023 Q1
Net sales 1 54.6 66.4 68.4
EBITDA - 2.8 -
EBIT 2 2.4 -
Operating Margin 3.66% 3.61% -
Earnings before Tax (EBT) - - -
Net income - - -
Net margin - - -
EPS - - -
Dividend per Share - - -
Announcement Date 23/05/22 17/08/22 -
1EUR in Million
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023 2024 2025
Net Debt 1 - - 8.17 - - - - -
Net Cash position 1 - - - 15.2 22.5 21.2 24.2 -
Leverage (Debt/EBITDA) - - 2.464 x - - - - -
Free Cash Flow 1 - - 13.8 13.9 17.1 2.96 9.2 -
ROE (net income / shareholders' equity) - - -4.89% 4.84% 5.61% 4.5% 6.6% -
ROA (Net income/ Total Assets) - - - - - - - -
Assets 1 - - - - - - - -
Book Value Per Share - - - - - - - -
Cash Flow per Share - - - - - - - -
Capex 1 1.06 - 0.85 0.29 1.02 0.95 0.89 -
Capex / Sales 0.39% - 0.36% 0.1% 0.41% 0.35% 0.32% -
Announcement Date 08/05/19 30/04/20 26/05/21 17/05/22 08/05/23 - - -
1EUR in Million
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Ratings for HAEMATO AG

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Quarterly revenue - Rate of surprise

Company calendar

Sector Specialty & Advanced Pharmaceuticals

1st Jan change Capi.
MERCK KGAA Stock Merck KGaA
+5.90% 71.83B
KYOWA KIRIN CO. LTD. Stock Kyowa Kirin Co. Ltd.
+22.78% 9.56B
YUHAN CORPORATION Stock Yuhan Corporation
+30.09% 4.85B
SK BIOPHARMACEUTICALS CO., LTD. Stock SK Biopharmaceuticals Co., Ltd.
-21.31% 4.48B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD. Stock Shenyang Xingqi Pharmaceutical Co.,Ltd.
+24.78% 3.9B
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD. Stock Shanghai Shyndec Pharmaceutical Co., Ltd.
+11.03% 2.01B
INDIVIOR PLC Stock Indivior PLC
-2.11% 1.99B
BETTA PHARMACEUTICALS CO., LTD. Stock Betta Pharmaceuticals Co., Ltd.
-36.28% 1.89B
CHANGCHUN BCHT BIOTECHNOLOGY CO. Stock Changchun BCHT Biotechnology Co.
-43.19% 1.77B
Specialty & Advanced Pharmaceuticals
  1. Stock Market
  2. Equities
  3. HAEK Stock
  4. HAEK Stock
  5. Financials HAEMATO AG